HepaRegeniX GmbH
PrivateLast Round
Series C
Extension
Apr 15, 2025
Total Funding Raised
$62.31M
Company Overview
HepaRegeniX GmbH operates in Healthcare & Life Sciences and is based in Tübingen. Its latest recorded funding round was a Series C Extension round in April 2025.
HepaRegeniX GmbH is a biotechnology company developing novel regenerative therapies for the treatment of acute and chronic liver diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HepaRegeniX GmbH Comparables
Compare HepaRegeniX GmbH with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Seal Rock Therapeutics | 80% | |
| SeaBeLife | 77% | |
| Galectin Therapeutics Inc | 77% |
For institutional investors. Book with your work email.
HepaRegeniX GmbH Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Apr 15, 2025 | ||||
| Series C | Jul 10, 2024 | ||||
| Series B | Jan 21, 2020 | ||||
| Series A | Jan 5, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
HepaRegeniX GmbH Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boehringer Ingelheim | Series B, Series C Extension, Series A |
| Ascenion | Series B, Series C Extension, Series C, Series A |
| Vesalius Biocapital Partners | Series C Extension |
| Novo Holdings | Series B, Series C Extension, Series C, Series A |
| Boehringer Ingelheim Venture Fund | Series B, Series C Extension, Series C, Series A |
| Wellington Partners | Series C Extension, Series C |
| High-Tech Gründerfonds | Series B, Series C Extension, Series C, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 11, 2025
HRX-233 targets kinase inhibitor resistance in KRAS-driven tumours.
- May 8, 2025
Presented development updates and clinical data for HRX-215 at EASL Congress 2025.
For institutional investors. Book with your work email.
HepaRegeniX GmbH Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about HepaRegeniX GmbH's valuation, stock price, and market status.
Is HepaRegeniX GmbH a public or private company?
HepaRegeniX GmbH is a private company.
What is the current stock price of HepaRegeniX GmbH?
HepaRegeniX GmbH is a private company, so its shares have no public market price. Caplight tracks HepaRegeniX GmbH's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is HepaRegeniX GmbH worth (valuation)?
Valuation information for HepaRegeniX GmbH is not publicly available.
Can I buy HepaRegeniX GmbH stock?
HepaRegeniX GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was HepaRegeniX GmbH's last funding round?
HepaRegeniX GmbH's most recent funding round was Series C Extension on April 15, 2025.
Who are the main investors in HepaRegeniX GmbH?
Key investors in HepaRegeniX GmbH include Boehringer Ingelheim, Vesalius Biocapital Partners, Novo Holdings, Boehringer Ingelheim Venture Fund.
Will HepaRegeniX GmbH IPO soon?
No public IPO plans have been announced for HepaRegeniX GmbH.
How can I track HepaRegeniX GmbH secondary market activity?
Caplight tracks bids, offers, and trades in HepaRegeniX GmbH's shares on secondary markets.